Hallucinations and Delusions in 1,715 Patients with Unipolar and Bipolar Affective Disorders

Black, Donald W.; Nasrallah, Amelia

doi:10.1159/000284576

Cited by 69 publications

(51 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous communication [6], we reported that mania was more likely to be associated with psychotic features than pri mary or secondary unipolar major depressive disorder. It has been pointed out that unipolar depression tends to have later age of onset than bipolar affective disorder [7], Therefore, illnesses that tend to have an early onset such as mania may be more severe by virtue of that fact.…”

Section: Discussionmentioning

confidence: 75%

Psychotic Symptoms and Age of Onset in Affective Disorders

et al. 1992

Self Cite

View full text Add to dashboard Cite

Prevalence of hallucinations and delusions was studied in 1,763 patients with unipolar major depression, bipolar affective disorder, and schizoaffective disorder. The authors found that the presence of psychotic features was negatively associated with age of onset for the group as a whole, and bipolar affective disorder (manic or mixed type) specifically. The clinical implications of the findings are discussed.

show abstract

Section: Discussionmentioning

confidence: 75%

Psychotic Symptoms and Age of Onset in Affective Disorders

et al. 1992

Self Cite

View full text Add to dashboard Cite

show abstract

“…Up to 20% of inpatients experience psychosis in the context of an acute bipolar depressive episode 322. The relative efficacy of various medications to treat these features in this phase of illness has not been examined, although clinical experience suggests that ECT and antipsychotics are highly effective for this population.…”

Section: Acute Management Of Bipolar Depressionmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

“…Several studies found that mood-congruent and mood-incongruent delusions may coexist in the same depressive episode [9][10][11] . In addition to this, it has been observed that the congruence of delusions with mood is sometimes difficult to evaluate, especially in persecutory delusions [12] , although so far no study has reported the frequency of this problem.…”

mentioning

confidence: 99%

Delusions in Major Depressive Disorder: Recommendations for the DSM-V

Maj¹

2007

Psychopathology

View full text Add to dashboard Cite

Hallucinations and Delusions in 1,715 Patients with Unipolar and Bipolar Affective Disorders

Cited by 69 publications

References 16 publications

Psychotic Symptoms and Age of Onset in Affective Disorders

Psychotic Symptoms and Age of Onset in Affective Disorders

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Delusions in Major Depressive Disorder: Recommendations for the DSM-V

Contact Info

Product

Resources

About